论文部分内容阅读
目的:研究经131I治疗后的格雷夫斯病(Graves disease,GD)病人发生甲状腺功能减退症(甲减)的相关危险因素。方法:对临床确诊的150例GD病人给予131I治疗,分析治疗后甲减与年龄、性别、病程、治疗前甲状腺质量、甲状腺最高摄131I率、每克甲状腺组织的摄131I剂量及131I总剂量、TGA、TMA的关系。结果:甲减组与非甲减组年龄、性别、病程、每克甲状腺组织的摄取131I剂量无显著性差异,两组间的治疗前甲状腺质量、甲状腺最高摄131I率及131I总剂量等因素有显著性差异。结论:131I治疗GD病人甲减的发生与治疗前甲状腺质量、甲状腺最高摄131I率及131I总剂量、TGA、TMA有关,与年龄、性别、病程、每克甲状腺组织的摄取剂量无关。
Objective: To study the risk factors of hypothyroidism (Hypothyroidism) in 131I-treated Graves disease (GD). Methods: One hundred and fifty-one patients with GD were enrolled in this study. The incidence of hypothyroidism, age, sex, course of disease, thyroid quality before treatment, highest 131I rate of thyroid, 131I dose per gram of thyroid tissue and 131I total dose were analyzed. TGA, TMA relationship. Results: There was no significant difference in age, sex, course of disease, 131I dosage per gram of thyroid tissue between hypothyroidism group and non-hypothyroidism group. The pretreatment thyroid mass, 131I highest thyroid uptake and 131I total dose Significant difference. CONCLUSION: The incidence of hypothyroidism in patients with GD treated with 131I is related to the thyroid mass before treatment, the highest thyroid uptake 131I, the total 131I dose, TGA and TMA, but not with age, sex, duration of disease and thyroid gland uptake.